Enhancing activity of FcαRI-bispecific antibodies using glycoengineering
The Journal of Immunology · 01.06.2025 · 214 (6) · 1261-1271
DOI: 10.1093/jimmun/vkaf027 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.03.2025. Verfasst von Céline A N Sewnath und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Killer Cells, Natural, Antibodies, Bispecific, Receptors, Fc. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Dutch Cancer Society, Name of Grant Holder: Prof. Dr Marjolein van Egmond.
Abstract (Originalsprache)
Macrophages and natural killer (NK) cells can effectively kill tumor cells in the presence of anti-cancer IgG monoclonal antibodies (mAbs), but neutrophils are less effective. We previously showed that IgG1 bispecific antibodies (BsAb), which target the IgA Fc receptor (FcαRI, CD89) and a tumor associated antigen induce effective neutrophil recruitment and tumor cell killing in vivo. Here we investigated if the efficacy of an anti-EGFR (CetuximAb)/FcαRI-bispecific antibody could be further improved by implementing glycoengineering of the IgG-Fc, aimed at increasing FcγRIIIa/b binding and/or complement activity. Fc afucosylation was introduced to enhance antibody-dependent cellular cytotoxicity (ADCC) by FcγRIIIa on NK/macrophages, which can also reduce neutrophil-mediated ADCC through their GPI-linked FcγRIIIb. Fc galactylation was found to enhance antibody hexamerization and thereby complement dependent cytotoxicity (CDC). Low fucosylated BsAbs moderately increased NK cell-mediated tumor cell killing, but did not affect neutrophil-mediated tumor cell killing nor phagocytosis by macrophages. Glycoengineering of these EGFR-specific BsAb, which normally are devoid of CDC-activity, did not enable their complement activities. In conclusion, glycoengineered FcαRI BsAbs increased ADCC by NK cells but had little effect on neutrophil or macrophage mediated tumor killing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Cancer Biology and Immunology Program, Amsterdam, The Netherlands.
- Amsterdam institute for Infection and Immunity, Cancer Immunology Program, Amsterdam, The Netherlands.
- Department of Immunopathology, Sanquin Research, Amsterdam, Netherlands.
- Department of Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands.
- Department of Proteomics and Metabolomics, Leids Universitair Medisch Centrum (LUMC), LUMC, The Netherlands.
ORCID-Profile: Céline A N Sewnath, Arthur E H Bentlage, Manfred Wuhrer, Gestur Vidarsson
Förderung
- KWF Dutch Cancer Society
- Name of Grant Holder: Prof. Dr Marjolein van Egmond
Zitieren
APA
Sewnath, C. A. N., Damelang, T., Bentlage, A. E. H., Ten Kroode, L., Tuk, C. W., Visser, R., Wuhrer, M., Van Coillie, J., Rispens, T., van Egmond, M., & Vidarsson, G. (2025). Enhancing activity of FcαRI-bispecific antibodies using glycoengineering. The Journal of Immunology, 214(6), 1261-1271. https://doi.org/10.1093/jimmun/vkaf027
Vancouver
Sewnath CAN, Damelang T, Bentlage AEH, Ten Kroode L, Tuk CW, Visser R, et al. Enhancing activity of FcαRI-bispecific antibodies using glycoengineering. The Journal of Immunology. 2025;214(6):1261-1271. doi:10.1093/jimmun/vkaf027
BibTeX
@article{Sewnath2025,
author = {Sewnath, Céline A N and Damelang, Timon and Bentlage, Arthur E H and Ten Kroode, Luuk and Tuk, Cornelis W and Visser, Remco and Wuhrer, Manfred and Van Coillie, Julie and Rispens, Theo and van Egmond, Marjolein and Vidarsson, Gestur},
title = {Enhancing activity of FcαRI-bispecific antibodies using glycoengineering},
journal = {The Journal of Immunology},
year = {2025},
volume = {214},
number = {6},
pages = {1261--1271},
doi = {10.1093/jimmun/vkaf027}
}
EUVIMED